Xing Yue

Experience

• 

  University of Illinois Urbana-Champaign

  Sept 2016 - Aug 2021

  Research Assistant

  My research interests include the fate and transport of emerging organic contaminants, antimicrobial resistance in the environmental dimension (especially selective pressures in the environment).Have accomplished 4 projects, resulting in 3 publications and 1 paper in preparation.1. Revealed that environmental levels of pesticides could stimulate and diversify the evolution toward higher antibiotic resistance2. Coupling the phenotypic antibiotic resistance evolution with genomic evolution through lab-based exposure experiments and next-generation sequencing technology 3. Investigated the occurrence and fate of emerging organic contaminants in wastewater treatment plants, pinpointing the role of an enhanced nitrification step in removing these contaminants.4. Investigated the effect of pesticides on antibiotic resistance evolution in pathogenic bacteria Show less

• 

  University of California, Riverside

  Jul 2019 - Apr 2022

  Visiting Project Scientist

  My research interests include emerging organic contaminants, antimicrobial resistance in the environmental dimension, and molecular mechanisms of antibiotic resistance. Have accomplished and currently working on several projects, including:1. Molecular mechanisms of antibiotic resistance induced by novel genetic mutations2. Effect of environmental factors on the selection of antibiotic resistance bacteria3. Occurrence of antimicrobials and other emerging organic contaminants in flooded water samples Show less

• 

  Wondfo USA

  Apr 2022 - now

  • Product/Assay Development and Validation: Leading the feasibility study of STI lateral flow tests and veterinary lateral flow tests (Canine Giardia and Parvovirus). Managed the validation studies (e.g., LOD, cross-reactivity, interference, stability studies, repeatability and reproducibility studies) of multiple lateral flow rapid tests, fluorescent immunoassays, and chemiluminescent immunoassays.• Tech Transfer: Led a multidisciplinary team (R&D, Manufacturing, Engineering, Quality, Regulatory) in the technology transfer of Covid/Flu Combo Rapid Antigen Test and Fentanyl Harm Reduction Test. Provided crucial insights and input for manufacturing (MFG) process improvement, and MFG capacity ramp-up, facilitated the establishment of new MFG equipment, and authored manufacturing SOPs, QC SOPs, process validation, and risk management reports. • Clinical Study and Regulatory Submissions: Contributed to clinical study protocol of Covid/Flu Combo Rapid Test, monitored and analyzed the clinical data and managed the progress by communicating with external CRO and clinical sites. Collaborated closely with NIH ITAP team to support the final regulatory document writing and reviewing for EUA and De Novo/510(k) submission. Successfully obtained FDA EUA approval and 510(k) registration for 3 LFA-based tests. Show less • Led product development of highly sensitive drug of abuse test to fentanyl (10 ng/mL) and its analogs for harm reduction use, including material screening (antibody, sample pad, conjugate pad, NC membrane), assay and buffer optimization, assay verification and validation, pilot lot manufacturing, and technology transfer• Led the development of RT-PCR assay and lateral flow antigen test for Monkeypox virus detection, RT-PCR assay for antibiotic resistant gonorrhea, including primer and probe design, assay/reagent optimization, and assay verification and validation. Involved in the optimization of flu antigen test. Contributed and supported research and development proposals to NIH ITAP and CARB-X funded programs• Designed and conducted preclinical studies (analytical studies including LOD, cross-reactivity, interference, hook effects, flex studies, stability studies, repeatability and reproducibility studies, usability studies) for lateral flow based COVID-19 antigen product (OTC and POC tests) and flu antigen products (POC test) to support FDA 510(k)/de novo, CLIA waiver submission, and Health Canada EUA submission• Closely work with external CROs for clinical studies of COVID-19 and Flu antigen test products. Contributed to clinical study protocols, managing the project progress of clinical studies by clinical site visit, study monitoring, and statistical analyses. communicating the clinical study updates with stakeholders, including C-suite management team, regulatory teams, and R&D teams• Established the platform of recombinant antibody development, including molecular cloning, ExpiCHO cell culture, transfection and transient expression, antibody purification and functional testing. Delivered four antibodies for use in immunoassay products Show less

  • Senior Scientist

    Jan 2024 - now

  • R&D Scientist

    Apr 2022 - Jan 2024